On Friday, Shares of MagneGas Corporation (NASDAQ:MNGA), skyrocketed 59.34% to $1.45.
MagneGas Corporation, declared that following a specific request from the US Navy, it has successfully accomplished a demonstration using its MagneGas2® cutting fuel at a designated US Navy facility. Following an initial demonstration, the US Navy contacted MagneGas and purchased their first order of MagneGas 2. Subsequently MagneGas was invited to perform a two-day “hands-on” demonstration and testing session that concluded on May 12th.
In various customer and independent tests, MagneGas2® has repeatedly been lauded for it’s ability to cut faster than acetylene in addition to for its overall safety advantages due to its lighter than air characteristics, reduced slag and reduced oxygen consumption. This particular US Navy facility is interested in improving productivity and discussions with them have been on-going for several months regarding demonstrating MagneGas 2 to their team.
MagneGas Corporation, an alternative energy company, creates and produces hydrogen based alternative fuel through the gasification of carbon-rich liquids in the United States and internationally. The company produces and distributes gas bottled in cylinders to the metalworking market as an alternative to acetylene.
Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA), declined -1.07% to $60.23, during its last trading session.
Teva Pharmaceutical Industries, declared that three company-sponsored abstracts will be presented at the 2015 American Thoracic Society (ATS) International Conference in Denver, Colorado on May 15-19, 2015.
Data to be presented comprise a Phase III study examining the functionality, reliability, accuracy and overall patient satisfaction of ProAir® RespiClick (albuterol sulfate) inhalation powder, which gained approval from the U.S. Food and Drug Administration (FDA) in March 2015. ProAir® RespiClick is now accessible by prescription and is indicated for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm in patients 12 years of age and older.
Additional Phase III data to be presented comprise a late-breaking abstract highlighting an interim analysis of the long-term safety and efficacy of Teva’s investigational anti-IL-5 therapy, reslizumab, in patients with asthma and elevated blood eosinophils. A third abstract to be presented comprises data from a dose-ranging study of fluticasone propionate multi-dose, dry-powder inhaler (MDPI) in adolescent and adult patients with asthma.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines.
At the end of Friday’s trade, Shares of Accenture plc (NYSE:ACN), gained 0.04% to $97.02, hitting its highest level.
Accenture, has reached a contract to acquire Javelin Group, a UK-based retail strategy consulting and digital transformation services provider. The acquisition will expand the capabilities of Accenture Strategy to assist the world’s leading retailers and consumer brands accelerate their digital transformation. Terms of the acquisition were not revealed, and completion of the acquisition is subject to regulatory approval and other customary closing conditions.
Following completion of the acquisition, Accenture Strategy will be able to offer a broader range of digital capabilities to shape innovative retail strategies and support the execution of large scale change. The combination of Javelin Group’s skills and Accenture’s global reach and industry expertise will enhance Accenture Strategy’s ability to serve a fast growing international retail market.
Accenture plc provides administration consulting, technology, and business process outsourcing services worldwide. The company’s Communications, Media & Technology segment offers enterprise and industry-customized services in network engineering and integration, field force enablement, and IP network migration; provides online customer and enterprise relationship administration services; and assists customers in developing video-over-IP platforms, and transforming legacy broadcast platforms to digital.
Finally, Cognizant Technology Solutions Corporation (NASDAQ:CTSH), ended its last trade with -0.39% gain, and closed at $63.57.
Cognizant Technology Solutions, declared that Purdue Pharma L.P., a leading pharmaceutical company, has selected Cognizant to optimize its core IT platform to improve business efficiency and drive enterprise agility.
Engaged in the research, development, production, and marketing of prescription and over-the-counter medicines and healthcare products, Purdue Pharma is an industry leader in pain medication research. To manage its complete range of business applications on the SAP platform, counting manufacturing, supply chain, and quality systems, Purdue Pharma is working with Cognizant to simplify and standardize its core application processes and create an environment for improved partnership among its entire ecosystem. This enables the company to focus on improving patients’ lives and serving the healthcare community.
At a new associated Purdue manufacturing facility in Durham County, North Carolina, Cognizant will assist extend Purdue’s core SAP and integrated application suite within the timelines defined by the project team for manufacturing commercial batches in the new plant.
Cognizant Technology Solutions Corporation provides information technology (IT), consulting, and business process services worldwide. The company operates through four segments: Financial Services, Healthcare, Manufacturing/Retail/Logistics, and Other.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
